Caroline Seymour

Bulumtatug fuvedotin produced a confirmed ORR of 32.08% and a DCR of 81.13% in recurrent or metastatic cervical cancer, with no treatment-related deaths.

Premal Thaker, MD, MS, discusses the role for CDK2 inhibition in platinum-resistant ovarian cancer.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.

Lurbinectedin alone or with irinotecan did not improve OS vs topotecan or irinotecan alone in patients with relapsed SCLC.

From hedgehog pathway mutations to next-generation sequencing, Vernon Sondak, MD, outlines a practical framework for complex BCC and CSCC workup.

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.

D. Ross Camidge, MD, PhD, reflects on his journey, from a gap year working at McDonald’s to directing the lung cancer program where he is now a patient.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

The FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

Sevabertinib has received priority review designation from the FDA in locally advanced or metastatic, HER2 TKD–mutant NSCLC.

Beth N. McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.

AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.

Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.

An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC

Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.

Top experts discuss the most important takeaways and data to come out of this year’s SGO Annual Meeting on Women’s Cancer.

iSCIB1+ has received fast track designation from the regulatory agency as a potential therapeutic options for patients with advanced melanoma.

The regulatory agency has set a PDUFA action date of February 27, 2027, for zipalertinib in locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Ris-rez plus adebrelimab led to an approximate 50% response rate and durable disease control in pretreated nonsquamous NSCLC without actionable mutations.

Amivantamab plus lazertinib improves second-line PFS vs osimertinib in EGFR-mutant NSCLC, per post hoc data from MARIPOSA presented at AACR 2026.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.